Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed

January 12, 2021 By The ASCO Post Staff

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The findings highlight the need for more effective treatments in this high-risk population (Abstract GS4-05).

Related Content